Abstract Number: 1439 • 2016 ACR/ARHP Annual Meeting
The EP4 Receptor Antagonist CR6086 Is More Effective Than Classical NSAID and DMARD Treatment in a Murine Model of Arthritis and in Human RA Synovial Explants
Background/Purpose: CR6086 is a novel small molecule acting as a potent and selective antagonist of the prostaglandin E2 (PGE2) receptor EP4 subtype (EP4 receptor). Recent…Abstract Number: 1439 • 2015 ACR/ARHP Annual Meeting
Reducing Gastric Ulcers in Patients with a History of Gastrointestinal (GI) Ulcers Who Require Long-Term High-Dose Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy
Background/Purpose: Patients ≥65 taking naproxen with previous GI symptoms have a 29% annual incidence of significant upper gastrointestinal events.(1) Those patients who are older, with…Abstract Number: 532 • 2013 ACR/ARHP Annual Meeting
Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis
Background/Purpose: Baseline inflammation has been shown to influence response to tumor necrosis factor alpha antagonist treatment in patients with axial spondyloarthritis (SpA). This study evaluated…
ACR Meeting Abstracts